Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study About Patients Using Copper Intrauterine Device (IUD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Egymedicalpedia.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Egymedicalpedia
ClinicalTrials.gov Identifier:
NCT01541241
First received: February 14, 2012
Last updated: February 28, 2012
Last verified: February 2012

February 14, 2012
February 28, 2012
January 2012
January 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01541241 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study About Patients Using Copper Intrauterine Device
Uterine Haemodynamic Changes in Patients With Copper Intrauterine Device Induced Bleeding

THE AIM OF THE this study is to assess the hemodynamic changes of uterine artery in patients with CIUD induced bleeding by using transvaginal color Doppler indices (uterine artery resistance index and pulsatility index) to prove the relationship between these changes and bleeding in these patient .

Intrauterine contraceptive device (IUD) is one of the most frequently used methods of birth control around the world. IUD induced irregular uterine bleeding is one of the main problems for many women using this method. In the first year of insertion of the IUDs, between 5 to 15% of women will have their IUDs removed because of bleeding. The use of IUD has been unfortunately associated with functional failure on one hand, and medical complications on the other hand. Despite the increasing use of intrauterine device, their further dissemination has been limited by high expulsion rates and the withdrawal of their use for medical reasons, mainly bleeding and pain.

Following insertion of modern copper IUD, menstrual blood loss increases by about 55%, and this level of bleeding continues for the duration of IUD use. These changes occur more rapidly, and iron supplementation is recommended.

There are several possible mechanisms that explain the cause of excessive bleeding in patients using IUD. Several studies reported that IUD insertion increase the production of prostaglandins in the endometrium which cause increased vascularity, vascular permeability, and inhibit platelet activity and therefore increase menstrual bleeding.

Recent studies have reported that IUD causes cyclo-oxygenase-2 (COX-2) up expression, the subsequent elevated prostanoid biosynthesis and signaling can promote the expression of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF) , basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), angioprotein-1 (Ang-1) and angioprotein-2 (Ang-2) or down-regulate the expression of anti-angiogenic genes such as cathepsin-D.

There are several mechanisms explaining the association of the pulsatility index (PI) and resistance index (RI) of uterine artery with menstrual blood loss. It has been suggested that menorrhagia, may be caused by an increased uterine secretion of prostanoids leading to impaired haemostasis.

Temporary post-insertion rise in prostaglandin concentrations coincided with the phase of increased bleeding and pain. There is over expression of mRNA and protein of COX-2 enzyme leading to overproduction of prostaglandins in the endometrium after the insertion of copper intrauterine device (CIUD).

Other vasoactive substances may also be involved, including nitric oxide (NO) which is a potent vasodilator produced the vascular endothelium. NO is present in the human endometrium and myometrium.

There is evidence that NO may play a part in acute and chronic inflammation. The introduction of intrauterine device into the uterine cavity induces a foreign body reaction in the surrounding endometrium. NO is present in the foreign body inflammatory reaction around loosened joint replacement implants. Thus, it is possible that IUD also induces NO synthesis in the surrounding tissue. There is also a connection between NO synthesis and prostaglandin synthesis. NO directly interacts with COX, which is responsible for prostaglandin synthesis and causes an increase in enzymatic activity.

There are also other possible mechanisms explaining the association of the PI of uterine artery with menstrual blood loss. Women with menorrhagia show a significant increase in endothelial cell proliferation, reflecting disturbed angiogenesis.

It is possible that there are also other vascular abnormalities resulting from disturbed angiogenesis. In abnormal vessels, poor contractibility and dysfunction of the haemostatic system may cause menorrhagia and decreased impedance. The expression of VEGF and its receptor, kinase insert domain-containing receptor (KDR) and microvessel density (MVD) were increased in endometrium after using CIUD.

Based on these findings, uterine artery Doppler indices RI, PI were widely investigated in order to identify the uterine hemodynamic changes in patients with IUD induced bleeding.

The protocol for this study will be approved by the local ethics committee, and informed consent will be obtained from the patients.

Every woman will be subjected to the following:

  • Complete history taking including age, parity, duration of CIUD use, timing of insertion of CIUD, history of other contraception method before insertion of CIUD, menstrual history before and after CIUD insertion including duration and amount of menstrual flow, regularity and length of the cycle, history of any drug intake, blood disease and any medical disorders were considered.
  • Clinical examination including general, abdominal, and pelvic examination.
  • Ultrasound examination will be done .After instructing the patients to empty their bladders, transvaginal ultrasound will done with the woman in the supine position with her legs semi-flexed and abducted to allow for easy manipulation of the vaginal probe at different angles with the application of the push-pull technique. A coupling gel will applied to the vaginal probe which was then introduced into a rubber glove and another layer of coupling gel was applied to the glove. The probe will then introduced into the vagina for systematic scanning.

Ultrasound examination will done on cycle days 2-5 unless there was continual bleeding, using a 7.5 MHz transvaginal transducer with color Doppler facilities . All the ultrasound measurements were measured between 9:00 and 11:00 am to eliminate diurnal variation.

The uterus and the ovaries will first visualized using conventional B-mode ultrasound to check the uterine size, the dimensions of its walls, presence of uterine masses and the accurate placement of the device inside the uterus.

Blood flow indices of the uterine artery will then calculated to obtain the pulsatility index (PI) and the resistance index (RI) according to the following equations: PI = (A - B)/mean, and RI = (A - B)/A, where A is the peak systolic, B is the end-diastolic Doppler shift, and the mean is the maximum Doppler shift frequency taken over the cardiac cycle. The mean PI and RI will calculated by combining three waveforms of the left and right uterine artery and were used for subsequent statistical analysis.

Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

primary care clinic, hospital out patient clinic

Copper Intrauterine Device Induced Bleeding
Not Provided
copper IUD used

Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.

Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding.

Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
May 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Regularly menstruating women before CIUD insertion.
  2. Age between 18 and 35 years.
  3. Hormonal treatment has not been taken at least two months before the study.
  4. Non steroidal anti-inflammatory drugs has not been taken 24 hours before the examination.

Exclusion Criteria:

  1. Pregnancy.
  2. The presence of pelvic pathology as ovarian cysts, pelvic endometriosis, endometrial polyps or fibrosis.
  3. Present or past history of pelvic inflammatory disease.
  4. Patients on hormonal treatment in the last two months before the study.
  5. Patients on non steroidal anti-inflammatory drugs last 24 hours before the examination.
Female
18 Years to 35 Years
Yes
Contact: Mohamed SE Elsafty, lecturer 01003922211 ext 002
Contact: Mohamed Elmandouh Mohamed, ass proff
Egypt
 
NCT01541241
Ayman-1
Yes
Egymedicalpedia
Egymedicalpedia
Not Provided
Principal Investigator: Ayman Abdelazim Elgamal, Residant Shoubra General Hospital
Egymedicalpedia
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP